ArticleTranslational andrology and urology2021

Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma.

Zhiling Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.